<i>In Vitro</i> Activity of Novel Topoisomerase Inhibitors against <i>Francisella tularensis</i> and <i>Burkholderia pseudomallei</i>
Antimicrobial resistance is a global issue, and the investigation of alternative therapies that are not traditional antibiotics are warranted. Novel bacterial type II topoisomerase inhibitors (NBTIs) have recently emerged as a novel class of antibiotics with reduced potential for cross-resistance to...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2023-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Antimicrobial resistance is a global issue, and the investigation of alternative therapies that are not traditional antibiotics are warranted. Novel bacterial type II topoisomerase inhibitors (NBTIs) have recently emerged as a novel class of antibiotics with reduced potential for cross-resistance to fluoroquinolones due to their novel mechanism of action. This study investigated the <i>in vitro</i> activity of a series of cyclohexyl-oxazolidinone bacterial topoisomerase inhibitors against type strains of <i>Francisella tularensis</i> and <i>Burkholderia pseudomallei</i>. Broth microdilution, time-kill, and cell infection assays were performed to determine activity against these biothreat pathogens. Two candidates were identified that demonstrated <i>in vitro</i> activity in multiple assays that in some instances was equivalent to ciprofloxacin and doxycycline. These data warrant the further evaluation of these novel NBTIs and future iterations <i>in vitro</i> and <i>in vivo</i>. |
|---|---|
| Item Description: | 10.3390/antibiotics12060983 2079-6382 |